TCEAL7

Across TCGA pan-cancer cohorts, TCEAL7 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TCEAL7 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TCEAL7 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TCEAL7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, LSCC, and GBM are the cancer types where TCEAL7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.808	0.323	.006	24	view →
LSCC	DFS	Median	III,IV	0.317	0.802	.016	7	view →
GBM	DFS	Median	All	0.815	0.657	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TCEAL7–PDAC (OS)

Open the PDAC breakdown →